FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer

23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma

23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...

Read more →

Woman denied cancer drug on NHS which could extend her life because of where she lives

22 January 2020 - Ann, 64, can't get the drug she needs to survive because it's not available on the NHS ...

Read more →

Roche wins approval for cancer drug Kadcyla in fast-growing China market

23 January 2020 - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another ...

Read more →

Old drug, new tricks: existing medicines show promise in fighting cancer

20 January 2020 - Dozens of compounds approved for other purposes can kill cancer cells selectively. ...

Read more →

Genprex receives U.S. FDA fast track designation for gene therapy that targets lung cancer

21 January 2020 - Genprex today announced that the U.S FDA has granted fast track Designation for Genprex’s Oncoprex immunogene ...

Read more →

US FDA grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

21 January 2020 - Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients. ...

Read more →

The biosimilar solution to expensive cancer care

20 January 2020 - In a recent column in Evidence-Based Oncology, Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer ...

Read more →

European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma

21 January 2020 - Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b. ...

Read more →

Janssen seeks expanded use of Imbruvica (ibrutinib) in combination with rituximab for patients with previously untreated chronic lymphocytic leukaemia

20 January 2020 - Application supported by the Phase 3 E1912 study evaluating the use of ibrutinib in combination with rituximab, ...

Read more →

European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible

20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex  (daratumumab) in combination with ...

Read more →

Lynparza regulatory submission granted priority review in the US for HRR-mutated metastatic castration-resistant prostate cancer

20 January 2020 - Submission based on PROfound, the first positive Phase III trial testing a targeted treatment in biomarker-selected ...

Read more →

NICE encourages further data collection on ‘game changing’ histology independent cancer drugs

17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...

Read more →

TG Therapeutics initiates rolling submission of new drug application to U.S. FDA for umbralisib as a treatment for patients with previously treated marginal zone lymphoma or follicular lymphoma

16 January 2020 - Completion of rolling submission for the MZL/FL NDA expected in 1H20. ...

Read more →

NICE ‘OK’ for Lynparza

16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...

Read more →